Fulminant encephalopathy with basal ganglia hyperintensities in HIV-infected drug users
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To define a clinical syndrome associated with active drug abuse in HIV-infected individuals.
Methods: We performed a retrospective review to identify individuals treated at the Johns Hopkins Hospital from 1993 to 2008 who were HIV-infected and were actively abusing drugs and had bilateral basal ganglia lesions on MRI. They were identified using a key word search in the radiology database, autopsy database, and the Moore HIV clinic database. Clinical, laboratory, and radiographic findings were correlated to define the syndrome.
Results: Ten individuals were identified who presented with a change in mental status or seizures, used cocaine or cocaine with heroin, had uncontrolled HIV infection (>190,000 copies/mL of plasma), elevated CSF protein (63–313 mg/dL), and diffuse hyperintense bilateral basal ganglia lesions on imaging. The majority of patients (8/10) had renal failure and despite supportive therapy most (7/9) ultimately died (median survival 21 days). Postmortem examination in one individual showed the presence of overwhelming microglial activation in the basal ganglia. The 2 surviving individuals were started on combined antiretroviral therapy (CART) during hospitalization.
Conclusion: We describe a unique clinical syndrome of a fulminant encephalopathy associated with primarily basal ganglia involvement in HIV-infected drug abusers. This syndrome is a rare but serious condition that is associated with a high mortality rate. Early CART institution may be useful and neuroprotective in this disorder, although this requires further investigation.
Footnotes
-
Study funding: Supported by a Sylvia Lawry Physician Fellowship from the National Multiple Sclerosis Society (S.D.N.) and NIH R01 DA024593 (A.N.).
-
- CART
- combined antiretroviral therapy
- FLAIR
- fluid-attenuated inversion recovery.
-
Supplemental data at www.neurology.org
- Received June 25, 2010.
- Accepted November 12, 2010.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
- Fulminant encephalopathy with basal ganglia hyperintensities in HIV-infected drug users
- Pasquale F. Finelli, Neurologist, Hartford Hospitalpfinell@harthosp.org
Submitted May 25, 2011 - Reply from the authors
- Scott Newsome DO, Department of Neurology, Johns Hopkins University, Baltimore, MD 21287anath1@jhmi.edu
- Avindra Nath MD
Submitted May 25, 2011
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complexL. Chang, T. Ernst, M. Leonido-Yee et al.Neurology, January 01, 1999 -
Articles
Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementiaL. Chang, T. Ernst, M. Leonido–Yee et al.Neurology, September 01, 1999 -
Article
HIV-associated motor neuron diseaseHERV-K activation and response to antiretroviral therapyLauren N. Bowen, Richa Tyagi, Wenxue Li et al.Neurology, September 24, 2016 -
Articles
Altered neurometabolite development in HIV-infected childrenCorrelation with neuropsychological testsM. A. Keller, T. N. Venkatraman, A. Thomas et al.Neurology, May 24, 2004